We have a vision for the future in which data, computing, networks, and other digital and deep technologies deliver meaningful outcomes and insight for improving health and the provision of care. We believe the creation of new businesses is built on in-depth understanding of the complex network of healthcare system participants, and marrying that with meaningful engineering innovation, advanced data science, and information technology-enabled products and services. We look for and seed founders determined to effectively and efficiently serve these participants on the european continent and internationally. We are committed to addressing needs across the care continuum, healthcare systems, and all specialties.

Nina Capital

Pitango VC is a venture capital firm focused on health-tech (Pitango Health-tech) and growth (Pitango Growth) investments in startups around the world in domains such as vertical SaaS, digital health, deep tech, fintech and insurance technology, devops, generative AI, Web3, and food tech. With two offices in Israel, Pitango currently manages several venture funds totaling over $2.8 billion in committed capital. It has invested in more than 250 companies.

Pitango VC

The Bertelsmann Investments division pools Bertelsmann's holdings in startups around the world.

Bertelsmann Investments

Boston Millennia Partners (BMP) has a long and successful history of growth capital investing on a national scope. Our Core Company Investment Strategy, combined with our international network of relationships and deep industry expertise, sets us apart from other investor groups and enables us to contribute meaningfully to our portfolio companies. The company focuses on investment opportunities within the healthcare and business services industries. Outsourcing and software as a service business companies are of particular interest for investment. Boston Millennia Partners' goal is to be supportive and effective investing partners, and establish productive relationships with its business partners that create long-term value. The company seeks to partner with entrepreneurs who share our goal of building enduring, large-scale businesses that result in personal fulfillment and superior financial returns.  Over the past thirty years, it has implemented an investment approach that centers on active participation with our portfolio companies.  Its goal is to be supportive and effective investing partners and establish productive relationships with its business partners that create long-term value.

Boston Millennia Partners

ATOORO is an Israeli investment family fund that targets to support innovative entrepreneurs and assist them to build great global companies. ATOORO invests across a number of key market segments including AgriFood Tech, Speech Recognition, Computer Vision, Perceptual computing, Natural language processing (NLP), Hacking prevention solution.

ATOORO FUND

Renegade Partners is a venture capital firm that helps founders navigate a pivotal phase of development while determining the size and impact they can ultimately achieve.

Renegade Partners

Shoni Health Ventures is an early stage venture capital fund that invests in digital health and medical devices.

Shoni Health Ventures

Accenture Ventures partners with growth-stage startups that create innovative and disruptive enterprise technologies using an open innovation.

Accenture Ventures

QuantHealth

QuantHealth is a company that creates artificial intelligence-based drug development data software that is used to run patient-centric medication simulations in order to speed and de-risk drug development. The company's software combines data points from across the clinical and drug development spectrum and predicts patient response to both approved and novel therapies, allowing pharma and biotech customers to run variations of their clinical trials to optimize trial design and increase the likelihood of trial success, enabling the discovery of new clinical opportunities and optimization strategies.

Israel-based QuantHealth provides a clinical trial simulation platform that allows pharmaceutical firms to conduct clinical trial simulations within a cloud-based environment, exploring thousands of variations within a minute. This platform utilizes an AI engine, which is trained on a dataset of 350 million patients and over 700,000 molecules, to facilitate the process. The company claims that its AI technology can forecast the results of trials with an accuracy rate of 86%.

Artificial intelligence is identifying and testing new therapies faster than ever.

AI Drug Discovery

Israel-based QuantHealth provides a clinical trial simulation platform that allows pharmaceutical firms to conduct clinical trial simulations within a cloud-based environment, exploring thousands of variations within a minute. This platform utilizes an AI engine, which is trained on a dataset of 350 million patients and over 100,000 molecules, to facilitate the process. Its AI-powered platform for drug discovery aims to reduce potential risks, optimize clinical trials, and predict patient responses to treatment. The company's model can predict clinical trial outcomes with 86% accuracy.

Incorporating technology to improve efficiency and success rate of clinical trials

Clinical Trial Technology

QuantHealth Appoints Dr. Adam Petrich, MD, As Its First Chief Medical Officer and Adam Goldberger As First Chief Financial Officer

Atropos Health

To leverage Atropos Health's real-world clinical data evidence and improve clinical trial predictions, reducing the 90% failure rate that costs pharmaceutical companies USD 45 billion annually.

Includes companies that provide digital data management platforms to collect and store patient reported outcome data. These platforms are also incorporating data analytics to help understand the results and identify trends and patterns. Additionally, the platforms enable connectivity with remote monitoring devices, including the Medical Internet of Things

Israel-based QuantHealth provides a clinical trial simulation platform that allows pharmaceutical firms to conduct clinical trial simulations within a cloud-based environment, exploring thousands of variations within a minute. This platform utilizes an AI engine, which is trained on a dataset of 350 million patients and over 700,000 molecules, to facilitate the process. The company claims that its AI technology can forecast the results of trials with an accuracy rate of 86%.In <a href="https://sp-edge.com/updates/24553">November 2023 </a>, it upgraded its platform with its new product, Katina, to simulate clinical trials on a large scale.&nbsp;Key customers and partnershipsIn March 2022, QuantHealth collaborated with <a href="https://4p-pharma.com/and-quanthealth-join-forces-to-conduct-ai-based-in-silico-clinical-trial-simulations/">4P-Pharma </a>to conduct in-silico clinical trials of its lead drug candidates.&nbsp;&nbsp;

<div>
 
 HiberCell is a biotechnology company that develops novel therapies focused on oncology. It entered the AI drug discovery space when it acquired AI genomics analysis company Genuity Science (and its subsidiaries in Iceland and Ireland) in August 2021.&nbsp;
 
 
 Genuity Science&rsquo;s solutions include end-to-end therapeutic discovery and development services such as building custom disease datasets, discovering and prioritizing targets, identifying biomarkers, and optimizing clinical trials. Genuity Science leverages its AI-powered platform to manage, process, and analyze genomic data. HiberCell intends to use Genuity Science&rsquo;s AI/ML capabilities to advance its oncology pipeline of five programs, of which one has reached the Phase 2 clinical trial stage.
 
 
 As of March 2024, the company&rsquo;s pipeline included three drug candidates, namely: 1) HC-7366, targeting the general control nonderepressible 2 (GCN2) kinase as part of the integrated stress response (ISR) signaling pathway; 2) HC-5404, aimed at inhibiting the PKR-like endoplasmic reticulum kinase (PERK) involved in the unfolded protein response (UPR) signaling pathway; and 3) odetiglucan, a therapy targeting tumor-immune interactions within the tumor microenvironment​.&nbsp;
 
 
 Key customers and partnerships
 
 
 In December 2023, HiberCell and Merck &amp; Co partnered to conduct a Phase Ib trial to evaluate the combination therapy of belzutifan and HC-7366 for treating clear cell renal cell carcinoma. Further, in January 2021, the company partnered with Biodesix to develop an enzyme-linked immunosorbent assay as a companion diagnostic test.
 
 
 Funding and financials
 
 
 In 
 <a href="https://hibercell.com/news/hibercell-closes-67-4-million-series-b-financing-and-secures-30-million-debt-facility-from-hercules-capital/">
 May 2021
 </a>
 , HiberCell completed a Series B financing round, raising USD 67.4 million, and secured an additional USD 30 million in debt financing from Hercules Capital. The funds were expected to be used for clinical advancement of its novel therapeutic candidates. 
 
</div>

HiberCell

<div>
 
 Arbor Biotechnologies specializes in gene editing to develop novel therapeutics for a variety of indications, starting with liver-related diseases. It operates an AI-powered biodiscovery platform to discover novel CRISPR enzymes, which are sequences of repeating genetic code. To do this, its platform deploys computational search techniques, genome sequencing, gene synthesis, and high-throughput screening. This can eventually be turned into drugs or even applied to agriculture and other industrial uses. In 2018, the company announced the discovery of Cas13d, a new type of gene editing enzyme that helps to alter RNA to treat genetic diseases.&nbsp;
 
 
 As of February 2024, the company had five internal drug discovery programs, of which one was in the IND-enabling stage. It also has multiple collaborative programs under development focused on oncology and various other therapeutic areas.
 
 
 Key customers and partnerships
 
 
 The company has a long-standing partnership with Vertex Pharmaceuticals since
 <a href="https://www.businesswire.com/news/home/20190103005194/en/Vertex-and-Arbor-Biotechnologies-Establish-Collaboration-to-Discover-Novel-Proteins-to-Advance-Discovery-of-Gene-Editing-Therapies">
 January 2019
 </a>
 , which focused on developing gene-editing treatments for cystic fibrosis and four other diseases. The alliance was further extended in 
 <a href="https://www.biospace.com/article/vertex-and-arbor-strike-a-1-2-billion-deal-for-gene-editing-programs/">
 August 2021
 </a>
 and 
 <a href="https://sp-edge.com/updates/15741">
 January 2023
 </a>
 .&nbsp;
 
 
 Other partnerships included a collaboration with 
 <a href="https://www.prnewswire.com/news-releases/arbor-biotechnologies-announces-collaboration-with-ginkgo-bioworks-to-advance-the-discovery-and-development-of-precision-gene-editors-302011991.html">
 Ginkgo Bioworks
 </a>
 (December 2023) to leverage Ginkgo's R&amp;D services to further optimize Arbor's novel precision editors, a non-exclusive licensing agreement with 
 <a href="https://www.globenewswire.com/news-release/2022/02/08/2380680/0/en/EdiGene-and-Arbor-Biotechnologies-Announce-Worldwide-Non-exclusive-License-Agreement-to-Advance-Ex-Vivo-Engineered-Cell-Therapy-Programs.html">
 EdiGene
 </a>
 (February 2022) to leverage Arbor&rsquo;s platform for ex vivo oncology therapies, a strategic research and non-exclusive licensing agreement with 
 <a href="https://investors.tcr2.com/news-releases/news-release-details/tcr2-therapeutics-and-arbor-biotechnologies-establish">
 TCR2 Therapeutics
 </a>
 (January 2022) to develop allogeneic TRuC T-cell therapies using Arbor&rsquo;s CRISPR technology, and a license agreement with 
 <a href="https://www.lonza.com/news/2020-12-23-14-00">
 Lonza
 </a>
 (December 2020) to use Arbor&rsquo;s gene-editing technology for Lonza&rsquo;s bioproduction products and services.
 
 
 Funding and financials
 
 
 In its latest Series B funding round in November 2021, which was led by Ally Bridge Group, TCG Crossover, and Temasek, Arbor Biotechnologies raised USD 215 million. The proceeds of the round were earmarked to fuel the company&rsquo;s clinical development pipeline.
 
</div>

Arbor Biotechnologies

Based in the UK, Arctoris provides an automated drug discovery platform, offering fully validated research and development (R&amp;D) processes under an Experiments-as-a-Service model. The company works with biotechnology companies, AI drug discovery companies, pharma and academic institutions enabling these institutions to run experiments in Arctoris’s platform and provides on-demand access to a broad scale of datasets for AI drug discovery companies to train their algorithms.

Arctoris

<div>
 
 Frontier Medicines leverages AI/ML technologies to develop treatments for cancer-causing proteins that are dismissed by traditional pharma companies as undruggable.&nbsp;
 
 
 The company has a proprietary chemoproteomic platform which entails an approach based on the interaction of small-molecule compounds and proteins to screen a large number of targets and combine them with a protein database that contains more than 150,000 novel binding pockets (hotspots). This enables it to access 90% of the human proteome that were not previously targeted due to lack of hotspots. The platform&rsquo;s AI/ML engine incorporates a library of diverse compounds, a hotspot map that serves as the starting point for understanding the druggability of a potential therapeutic target, and lead design and generation.&nbsp;
 
 
 The company focuses on oncology and immunology target and, as of February 2024, it had five wholly-owned therapeutic programs and three AbbVie-partnered programs in its pipeline. All programs were in their discovery stage, except the company&rsquo;s lead candidate, FMC-376 (activated and inactivated forms), focused on treating different cancer types, including non-small cell lung cancer (NSCLC), colorectal carcinoma (CRC), and pancreatic ductal adenocarcinoma (PDAC), which is in the IND-enabling stage.
 
 
 Key customers and partnerships
 
 
 The company entered a USD 100 million partnership with 
 <a href="https://news.abbvie.com/2020-12-02-AbbVie-and-Frontier-Medicines-Establish-Global-Partnership-to-Discover-and-Develop-Novel-Therapies-and-E3-Degraders-Against-Difficult-to-Drug-Targets">
 AbbVie
 </a>
 In December 2020 to develop small-molecule therapeutics against hard-to-drug protein targets including around 600 E3 ligases (the enzymes that drive the ubiquitination and degradation of proteins.&nbsp;
 
 
 Funding and financials
 
 
 In July 2021, the company raised USD 88.5 million in a 
 <a href="https://sp-edge.com/updates/4347">
 Series B
 </a>
 funding round co-led by Woodline Partners LP and RA Capital Management, with equal participation from Deerfield Management Company. The proceeds were earmarked for advancing the company&rsquo;s drug pipeline and expanding operations in Boston, where its new facility was to complement the company&rsquo;s headquarters in California. 
 
</div>

Frontier Medicines

<div>
 
 Verge Genomics is a biotechnology company engaged in developing therapeutics for neurological diseases using human genomics and AI to accelerate drug discovery. The main target areas are Amyotrophic Lateral Sclerosis (ALS), Parkinson&rsquo;s Disease (PD), and Frontotemporal Dementia (FTD).&nbsp;
 
 
 It has built a proprietary all-human platform (unlike standard clinical trials that rely on animal data), called CONVERGE, that uses data sets from brain tissue samples of deceased patients with ALS and PD. While most drugs target only one gene at a time, the company claims its technology can identify hundreds of genes that cause disease and develop drugs that target all the genes at the same time. The company uses AI technology to optimize the drug discovery process as a whole.
 
 
 As of March 2024, Verge had one drug candidate in the clinical stage (Phase I) and 10 drug candidates in the discovery stage.&nbsp;
 
 
 Key customers and partnerships
 
 
 The company has partnerships with various tissue banks (such as Harvard University and University of Miami Miller School of Medicine) and several educational institutes and foundations (such as Target ALS, Answer ALS) that enabled its drug discovery platform.&nbsp;
 
 
 In addition, the company&rsquo;s customers include several pharmaceutical companies, such as 1) 
 <a href="https://www.vergegenomics.com/news-blog/verge-genomics-announces-research-collaboration-with-the-sheffield-institute-for-translational-neuroscience">
 Sheffield Institute for Translational Neuroscience (SITraN)
 </a>
 to accelerate the validation of novel drug targets and screening of drug compounds for Parkinson's disease (February 2021), 2) 
 <a href="https://sp-edge.com/updates/4146">
 Eli Lilly
 </a>
 to research and develop novel therapies to treat ALS (July 2021), 3) 
 <a href="https://sp-edge.com/updates/21707">
 Alexion
 </a>
 to identify novel drug targets for rare neurodegenerative and neuromuscular diseases (September 2023), and 4) 
 <a href="https://www.vergegenomics.com/news-blog/verge-genomics-and-the-pritzker-neuropsychiatric-disorders-research-consortium-form-cutting-edge-schizophrenia-research-collaboration">
 Pritzker Neuropsychiatric Disorders Research Consortium
 </a>
 to analyze data from schizophrenic patient&rsquo;s brain tissue with Verge&rsquo;s technology (October 2023).
 
 
 Funding and financials
 
 
 In December 2021, Verge raised USD 98 million in an oversubscribed 
 <a href="https://sp-edge.com/updates/7426">
 Series A
 </a>
 funding round led by BlackRock. The funds were used to scale up its pre-clinical and clinical candidate programs in the pipeline and enhance its lead therapeutics through clinical testing. 
 
</div>

Verge Genomics

SaaS (Software-as-a-Service) companies providing their ML platform to other pharma companies for drug discovery services such as target selection, validation and lead optimization.

SaaS (Software-as-a-Service) companies providing their ML platform to other pharma companies to design and run preclinical experiments.

SaaS (Software-as-a-Service) companies providing their ML platform to other pharma companies to identify biomarkers (measurable biological signs used to determine disease progression) and predict drug response.

SaaS (Software-as-a-Service) companies aggregating and analyzing biomedical data with the help of AI to generate insights across the drug development pipeline.

Biotechnology companies that have integrated AI as a core component of their in-house drug development process. They typically have a few in-house drug development programs, and also collaborate with pharma companies to develop certain drugs.

Includes companies that use GenAI as a core part of their product offering for drug discovery & development

Companies leverage GenAI to support drug discovery through accelerated drug designing

Companies offer AI/ML-based SaaS products to accelerate the discovery and development of novel therapeutics

Offers AI/ML-based solutions to accelerate drug discovery and development

Israel-based QuantHealth provides a clinical trial simulation platform that allows pharmaceutical firms to conduct clinical trial simulations within a cloud-based environment, exploring thousands of variations within a minute. This platform utilizes an AI engine, which is trained on a dataset of 350 million patients and over 100,000 molecules, to facilitate the process. Its AI-powered platform for drug discovery aims to reduce potential risks, optimize clinical trials, and predict patient responses to treatment. The company's model can predict clinical trial outcomes with 86% accuracy.The company noted that, as of June 2024, its platform had over 1 trillion data points, served over 350 million patients, and was used in over 180,000 clinical trials.Key customers and partnershipsIn <a href="https://4p-pharma.com/and-quanthealth-join-forces-to-conduct-ai-based-in-silico-clinical-trial-simulations/">March 2022</a>, QuantHealth collaborated with 4P-Pharma to conduct in-silico clinical trials of its lead drug candidates.Most recently, in <a href="https://sp-edge.com/updates/37186">December 2024</a>, the QuantHealth partnered with Atropos Health a provider of real-world clinical data evidence, to leverage over 300 million patient records for improving clinical trial predictions. Through Atropos Health's Evidence Network, QuantHealth planned to deploy AI models at the point of care to match patients with clinical trials based on current and future eligibility status, as well as their likelihood to benefit from the trial.

Headquartered in Amsterdam, Castor is a cloud-based e-clinical data platform that can be used for a range of tasks and processes during a clinical trial. It offers four solutions: 1) electronic data capture (EDC) to capture and process data from multiple sources including researchers, 2) electronic patient-reported outcomes (ePRO) to collect and manage patient-reported data on a centralized platform, 3) e-consent - to enable patients to be recruited, screened, and enrolled remotely, and 4) a decentralized clinical trials (DCT) platform to assist operators with managing DCT technologies and devices through a central platform. The company’s solutions are targeted at industries like biotech and pharma, diagnostics, and clinical research organizations. Its solutions are built in line with industry-standard compliance and data protection standards including HIPAA, GDPR, and ISO 27001.Castor aimed to collect enough clinical trial research data to enable the reuse of data for AI-driven clinical trials, which would lower the costs of operating clinical trials and reduce the time taken to bring new drugs to market.Key customers and partnershipsAs of June 2024, the company had supported 14,000+ studies and 6 million patients through clinical trials across 90+ countries, since launching in 2007. In terms of therapeutic areas, Castor had supported a range of different areas, including oncology, cardiovascular diseases, and diabetes. The company had been engaged by 500+ organizations, including the World Health Organization, Click Therapeutics, and Stryker. It was the first to incorporate machine learning into its system for the identification of Covid-19 patients. The company offered free access to its system for Covid-19 research projects, with over 200 projects using the platform as of June 2022. In February 2024, the company partnered with Microsoft to use Microsoft Azure to bring modern AI to clinical trials. The feature was released to help Castor users develop their studies faster by simplifying complex tasks in the study build process. The company additionally noted that it was planning to release its first in a line of Practical AI features to all its users in public Beta. Funding and financialsThe company raised USD 45 million in Series B funding in July 2021, led by Eight Roads Ventures and F-Prime Capital. The funds were earmarked for product development, interoperability with partner systems, and market research on decentralized trials. The company had a headcount of 150 at the time of the Series B and was planning to expand to 200 by the end of 2021.

Castor

Florence Healthcare offers a platform for clinical trial management. It has four key components: 1) SiteLink to start-up and monitor remote clinical sites, 2) eBinders to digitize and store research binders, 3) eConsent to simplify and digitize the consent process, and 4) Electronic Trial Master File to digitize the storage and transfer of files between sites and research sponsors. The platform is compliant with standard industry requirements including HIPAA, 21 C.F.R Part 11, ICF/GCP, and GDPR.Key customers and partnershipsAs of June 2024, Florence supported over 18,000 research sites, across 55+ countries, with key customers including Pfizer. The usage of the company’s software tripled in 2020, driven by an industry shift toward digitalization as a result of the Covid-19 pandemic. In February 2022, the company was ranked as the best clinical trial platform out of a group of 190 for ease of setup, ease of use, and customer support.Florence partnered with Greenphire, a company focusing on patient convenience and financial management for clinical trials, in Janauary 2024. Through the partnership, Florence's platform will be integrated with Greenphire's to improve payment systems within clinical trials. Benefits of the partnership included reduced manual work for sites, faster payments, and better visibility of site activity for sponsors and Contract Research Organizations (CROs). Funding and financialsThe company raised USD 80 million in Series C funding in May 2021 led by Insight Partners. The proceeds were to be used to scale up its sales and marketing teams and improve the value proposition of the platform by reducing the time required by customers to implement and manage clinical trials.

Florence Healthcare

Huma is a UK- and US-based clinical trial tech startup that provides a digital platform to manage clinical trials, including decentralized clinical trials. The platform can be used throughout the clinical trial process, including patient recruitment, screening, electronic consent, clinical outcome assessments, patient-reported outcomes, and telemedicine. The platform is built up to industry standards in data privacy and security, including ISO 27001, 21 C.F.R. Part 11, and TxP.In June 2023, the company <a href="https://sp-edge.com/updates/19352">received FDA 510(k) Class II FDA clearance </a>for its configurable disease-agnostic platform, including its cardiovascular risk score algorithm. The company received this FDA clearance in partnership with Health Canada and it allows Huma's platform to be used to monitor patients of all ages with any condition, including pediatrics and pregnancy. The Class II clearance also enables the platform to host algorithms that provide automated AI-driven data analytics for diagnosis, screening, clinical decision-making, predictions on health outcomes, and recommendations on dosage.In July 2024, the company was <a href="https://sp-edge.com/updates/31552">estimated to be valued at nearly USD 1 billion</a> when it secured a Series D investment of USD 80 million. Key customers and partnershipsSome of the key partners working with Huma include AstraZeneca, Johnson &amp; Johnson, Bayer, Stanford University, and the University of Cambridge. As of July 2024, the platform supported 3,000+ hospitals and clinics, screened over 35 million individuals, and had 1.8 million active users across 70 countries. Huma was awarded the 2021 Prix Galien Award, which is widely considered the “Nobel Prize” for pharmaceuticals and life sciences.The company announced a partnership with Xyla Elective Care in June 2022, to provide support to the UK’s National Health Service in delivering and managing virtual wards.

Huma

Based in California and founded in 2015, Medable is a digital clinical trial management platform with a range of modules for different processes. These modules include a decentralized clinical trial platform to support decentralized trials using remote tools for data gathering, monitoring, televisits, and consent; digital patient screening to screen patients remotely and at scale; e-consent to enable patients to digitally consent for clinical trials; electronic clinical outcome assessments; and patient-reported outcomes to document data in real time and provide easy access for researchers. It also includes remote patient monitoring to make it easy for patients to record and share data with clinical research teams.Medable operates on a SaaS business model, with customers having the option of selecting and deploying only the modules required as part of their uniquely customized solution.In <a href="https://sp-edge.com/updates/32647">August 2024</a>, Medable launched 'Medable Studio', an all-in-one application for configuring, translating, validating, and launching electronic clinical outcome assessment (eCOA) Plus solutions (which include eCOA, e-consent, televisits, and sensors) into clinical trials. The no-code suite aimed to simplify the complex eCOA launch process, offering biopharmaceutical companies greater control and transparency. Medable Studio includesda point-and-click builder for creating assessments and instruments, a visual schedule of assessments builder, a translation workbench, and a content library. The platform enabled users to rapidly build and launch complex clinical trials, with the ability to create protocol-fit study designs in hours instead of months.In <a href="https://sp-edge.com/updates/35913">November 2024</a>, Medable launched Medable AI, a suite of GenAI capabilities integrated into its Studio platform. The suite aimed to streamline digital and decentralized clinical trials for sponsors and research organizations. The AI suite features automated eCOA creation that converts existing outcome assessments into a digital format, a ChatGPT-like interface for editing assessments, and scalable assessment-generation capabilities.&nbsp;As of <a href="https://hitconsultant.net/2024/10/30/medable-partners-with-google-cloud-to-accelerate-clinical-trials/">October 2024</a>, the company offered its platforms across 60 countries and was used across 300 decentralized and hybrid clinical trials. The company’s platform is compliant with industry standards, including HIPAA, FDA’s 21 CFR Part 11, and GDPR.Key customers and partnershipsAs of <a href="https://www.businesswire.com/news/home/20240607926468/en/Medable-Wins-2024-Prix-Galien-UK-Award-for-Best-Digital-Health-Solution">June 2024</a>, Medable claimed to work with 14 out of the top 20 pharmaceutical companies, in addition to working with a range of partners, including Cognizant, Accenture, Oracle, and PwC.In <a href="https://sp-edge.com/updates/35456">October 2024</a>, the company partnered with Google Cloud to offer its decentralized clinical trial platform on Google Cloud's marketplace. The collaboration combined Medable's clinical trial technology with Google Cloud's infrastructure and AI capabilities to streamline trial processes.In <a href="https://sp-edge.com/updates/29843">May 2024</a>, Medable partnered with Masimo, a medical technology provider, to incorporate new wearable devices in clinical research. Medable announced it would include the MightySat Rx pulse oximeter by Masimo in its platform for various major clinical trials, particularly in lung and breast cancer research.In <a href="https://sp-edge.com/updates/22394">October 2023</a>, the company partnered with Pluto Health, a healthcare coordination company, to enhance the clinical trial experience for participants and improve data collection during trials. Through the partnership, the companies aimed to connect patients to the right medical resources including access to clinical trials and home delivery of medication.&nbsp;In <a href="https://www.fiercebiotech.com/biotech/gsk-taps-medable-decentralized-clinical-trials-patient-diversity">September 2022</a>, the company announced a four year agreement with GlaxoSmithKline to use Medable’s platform for clinical trials across multiple products. Financial terms of the agreement were not disclosed.

Medable

Headquartered in New York, Obvio Health provides a full service for clients, supporting them throughout the clinical trial process from the design and recruitment stages to outcome measurement and reporting. In addition to its technological platform, the company provides professional services to execute clinical trials using its in-house clinical operations team. The platform caters to 17 therapeutic areas, including cardiology, oncology, respiratory, men's and women's health, dermatology, gi, hepatology, mental health, oral health, and infectious disease (Covid-19). The platform is compliant with industry standards including 21 CFR Part 11, ICH-GDP, GDPR, and ISO 27001.According to the company, its platform was designed from the ground up to cater to digital trials run by virtual clinical teams, which resulted in faster patient recruitment (three months for Obvio compared to 12 months for physical site trials). In January 2022, the company launched an augmented electronic patient-reported outcome (augmented ePRO) module, which incorporates AI and manual scoring by experts/clinicians. The company claims this improves the accuracy and quality of data collected.In April 2024, the ObvioHealth launched ObvioGo 2.0, an enhanced platform and mobile application designed to meet the unique needs of trial sites and sponsors. The upgraded platform allows the combination of hybrid and virtual trial designs within one study. It includes features such as the ability to create site-specific workflows, integration with other clinical systems, and a streamlined translation process. Additional features include a built-in virtual assistance team, COACH, for trial tasks support and a patient identifier tool for patient registration and data correlation.As of June 2024, the platform catered to 17 therapeutic areas, including cardiology, oncology, respiratory, men's and women's health, dermatology, GI, hepatology, mental health, oral health, and infectious disease (Covid-19). The platform is compliant with industry standards including 21 CFR Part 11, ICH-GDP, GDPR, and ISO 27001.Key customers and partnershipsAs of June 2024, Obvio Health’s client base included companies like GlaxoSmithKline, Pfizer, Bayer, Danone, and General Mills. As of June 2024, the company’s operations were spread over 28 countries and had supported obtaining consent from 40,000+ patients across 40 clinical trials since its launch.In March 2022, Obvio partnered with Renovia to conduct the first fully virtual trial in urogynaecology, based on Renovia’s Leva device. The device helped patients with performing kegel exercises more effectively, in addition to monitoring compliance over the trial period.In November 2023, Obvio then partnered with Chemist Warehouse, the largest retail pharmacy chain in Australia, to improve the reach and efficiency of clinical trials. Through the partnership, Chemist Warehouse agreed to promote ObvioHealth-managed trials to its customers in Australia, using both offline and online channels. Additionally, ObvioHealth agreed to utilize Chemist Warehouse's Telehealth services for studies that require clinician assessments. The collaboration aimed to increase the awareness and convenience of clinical trials, addressing two major hurdles in participant recruitment. The long-term goal of the partnership was to expedite the introduction of innovative therapies to the market more efficiently and economically.&nbsp;

Obvio Health

Companies offering data and workflow management platforms and solutions to assist with the operational management of a clinical trial, including site management, monitoring processes in terms of risk and documentation, and payment automation

Companies using remote patient monitoring tools and other connectivity solutions to enable remote collection of patient data and monitoring and run trials virtually without requiring the patient to be physically present at the clinical trial site

Companies that offer workflow management platforms that are used to manage logistics tasks and processes for clinical trials, primarily the randomization of assigning patients in a clinical trial and automation of logistics workflows based on clinical trial data

This is the use of software, incorporating AI and machine learning technology to improve the matching process of patients with suitable clinical trials

Companies that offer software solutions for identifying and evaluating potential trial sites, along with documentation and workflow management systems to complete the processes before launching, including electronic patient consent and other required regulatory tasks

Companies that provide software tools that help with the design of clinical trials, including identifying protocol violations, collecting participant input on potential design ideas for the trial, and crowdsourcing of protocol ideas for clinical trials

Companies that use GenAI as a core part of their product offering for Clinical Trial Tech

Startups in this hub use IoT to support report patient monitoring and data gathering

AI/ML algorithms can be used to automate the analysis of patient data

Offers digital platforms that accelerate clinical trials and evaluations

Most CTT platforms are offered on a B2B basis to companies carrying out clinical trials

Startups in this hub seek to improve clinical trial diversity by including underrepresented communities

Clinical Trial Technology providers incorporate GenAI to enhance their platform’s capabilities and utility

ANALYST_QUICK_TAKE

PROMINENT_CATEGORY

<div>

 QuantHealth and Atropos Health have formed a partnership to use 300 million patient records with the purpose of enhancing the accuracy of clinical trial predictions. QuantHealth's AI-driven drug development platform will be utilised through Atropos Health's Evidence Network. The AI models will be deployed to pair patients with clinical trials based on their current and future eligibility, as well as their potential to benefit from the trial.
 The collaboration aims to increase efficiency in trial design, recruitment, and execution, with a focus on decreasing the current 90% failure rate of drugs at the clinical stage, which results in USD 45 billion of annual costs for pharmaceutical companies.
 The partnership leverages QuantHealth's proven track record. The platform has previously simulated over 100 clinical trials with a success rate of 85%, generating USD 215 million in returns for eight of the top 20 pharmaceutical companies globally.

</div> Analyst QuickTake: 
 In <a href="https: 
//www.atroposhealth.com/atropos-health-leverages-google-cloud/"> January </a> , Atropos Health partnered with Google Cloud to simplify access to data, streamline analytics, and democratize insights. Through the latest partnership, QuantHealth might also benefit from expedited functionality of Atropos’ platform.

QuantHealth

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless